Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257319 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4774305 | 0.94 | ALDH1A1 (0.38) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4774303 | 0.94 | ALDH1A1 (0.38) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4167131 | 0.80 | ALDH1A1 (0.49) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4167134 | 0.80 | ALDH1A1 (0.49) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL1531396 | 0.79 | ALDH1A1 (0.45) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL1531393 | 0.79 | ALDH1A1 (0.45) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4181610 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4181600 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4169597 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHRHTTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-1986646-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093363-A1 | NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | ALDH1A1 1981/4885TSHR 533/4885HTT 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.